Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 10/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767386 | 1.00 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18261034 | 0.92 | NPC1 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260694 | 0.88 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL766825 | 0.88 | GAA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18261078 | 0.88 | CYP4F2 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30259618 | 0.88 | RORC (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260817 | 0.88 | RORC (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL767343 | 0.87 | RXRA (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL20163366 | 0.87 | GCK (0.33) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL18260924 | 0.87 | CYP4F2 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CYP4F2 3533/4885CYP4A11 2858/4885RXRA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.